MovDisordV3, Main, Exploration, bibRecord, 003416

Glutamate release inhibition ineffective in Levodopa‐induced motor complications

Identifieur interne : 003416 ( Main/Exploration ); précédent : 003415; suivant : 003417

Glutamate release inhibition ineffective in Levodopa‐induced motor complications

Auteurs : William Bara-Jimenez [États-Unis] ; Tzvetelina D. Dimitrova [États-Unis] ; Abdullah Sherzai [États-Unis] ; Murat Aksu [États-Unis] ; Thomas N. Chase [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2006-09.

RBID : ISTEX:727CE333D0A3B5149486C6E9C88173522ED07D5D

English descriptors

KwdEn :
- Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Dyskinesia, Drug-Induced (drug therapy), Excitatory Amino Acid Antagonists (therapeutic use), Female, Glutamic Acid (metabolism), Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson's disease, Riluzole (adverse effects), Riluzole (therapeutic use), Treatment Outcome, dopamine, dyskinesias, levodopa, glutamate, riluzole, striatum.
MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa, Riluzole.
- chemical , metabolism : Glutamic Acid.
- chemical , therapeutic use : Antiparkinson Agents, Excitatory Amino Acid Antagonists, Levodopa, Riluzole.
- drug effects : Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Treatment Outcome.

Abstract

Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3‐week, double‐blind, proof‐of‐concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa‐induced motor complication severity. Opposing effects of a generalized inhibition of glutamate‐mediated synaptic transmission may limit the usefulness of this approach to treat PD. © 2006 Movement Disorder Society

Url:

https://api.istex.fr/document/727CE333D0A3B5149486C6E9C88173522ED07D5D/fulltext/pdf

DOI: 10.1002/mds.20976

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Glutamate release inhibition ineffective in Levodopa‐induced motor complications</title>
<author><name sortKey="Bara Imenez, William" sort="Bara Imenez, William" uniqKey="Bara Imenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
</author>
<author><name sortKey="Dimitrova, Tzvetelina D" sort="Dimitrova, Tzvetelina D" uniqKey="Dimitrova T" first="Tzvetelina D." last="Dimitrova">Tzvetelina D. Dimitrova</name>
</author>
<author><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name>
</author>
<author><name sortKey="Aksu, Murat" sort="Aksu, Murat" uniqKey="Aksu M" first="Murat" last="Aksu">Murat Aksu</name>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:727CE333D0A3B5149486C6E9C88173522ED07D5D</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20976</idno>
<idno type="url">https://api.istex.fr/document/727CE333D0A3B5149486C6E9C88173522ED07D5D/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003585</idno>
<idno type="wicri:Area/Istex/Curation">003585</idno>
<idno type="wicri:Area/Istex/Checkpoint">001E76</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Bara Imenez W:glutamate:release:inhibition</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16758479</idno>
<idno type="wicri:Area/PubMed/Corpus">002C11</idno>
<idno type="wicri:Area/PubMed/Curation">002C11</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D07</idno>
<idno type="wicri:Area/Ncbi/Merge">001723</idno>
<idno type="wicri:Area/Ncbi/Curation">001723</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001723</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Bara Jimenez W:glutamate:release:inhibition</idno>
<idno type="wicri:Area/Main/Merge">004730</idno>
<idno type="wicri:Area/Main/Curation">003416</idno>
<idno type="wicri:Area/Main/Exploration">003416</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Glutamate release inhibition ineffective in Levodopa‐induced motor complications</title>
<author><name sortKey="Bara Imenez, William" sort="Bara Imenez, William" uniqKey="Bara Imenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dimitrova, Tzvetelina D" sort="Dimitrova, Tzvetelina D" uniqKey="Dimitrova T" first="Tzvetelina D." last="Dimitrova">Tzvetelina D. Dimitrova</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Aksu, Murat" sort="Aksu, Murat" uniqKey="Aksu M" first="Murat" last="Aksu">Murat Aksu</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-09">2006-09</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">9</biblScope>
<biblScope unit="page" from="1380">1380</biblScope>
<biblScope unit="page" to="1383">1383</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">727CE333D0A3B5149486C6E9C88173522ED07D5D</idno>
<idno type="DOI">10.1002/mds.20976</idno>
<idno type="ArticleID">MDS20976</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Excitatory Amino Acid Antagonists (therapeutic use)</term>
<term>Female</term>
<term>Glutamic Acid (metabolism)</term>
<term>Humans</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson's disease</term>
<term>Riluzole (adverse effects)</term>
<term>Riluzole (therapeutic use)</term>
<term>Treatment Outcome</term>
<term>dopamine</term>
<term>dyskinesias, levodopa</term>
<term>glutamate</term>
<term>riluzole</term>
<term>striatum</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
<term>Riluzole</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Glutamic Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Levodopa</term>
<term>Riluzole</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Reported benefits of various glutamatergic receptor antagonists in Parkinson's disease (PD) prompted an evaluation of the antidyskinetic effect of a putative glutamate release inhibitor in 15 moderately advanced patients. In a 3‐week, double‐blind, proof‐of‐concept study, riluzole (200 mg/day) failed to alter parkinsonian or levodopa‐induced motor complication severity. Opposing effects of a generalized inhibition of glutamate‐mediated synaptic transmission may limit the usefulness of this approach to treat PD. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Bara Imenez, William" sort="Bara Imenez, William" uniqKey="Bara Imenez W" first="William" last="Bara-Jimenez">William Bara-Jimenez</name>
</region>
<name sortKey="Aksu, Murat" sort="Aksu, Murat" uniqKey="Aksu M" first="Murat" last="Aksu">Murat Aksu</name>
<name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<name sortKey="Dimitrova, Tzvetelina D" sort="Dimitrova, Tzvetelina D" uniqKey="Dimitrova T" first="Tzvetelina D." last="Dimitrova">Tzvetelina D. Dimitrova</name>
<name sortKey="Sherzai, Abdullah" sort="Sherzai, Abdullah" uniqKey="Sherzai A" first="Abdullah" last="Sherzai">Abdullah Sherzai</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003416 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003416 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:727CE333D0A3B5149486C6E9C88173522ED07D5D
   |texte=   Glutamate release inhibition ineffective in Levodopa‐induced motor complications
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Glutamate release inhibition ineffective in Levodopa‐induced motor complications

Glutamate release inhibition ineffective in Levodopa‐induced motor complications

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.